Ms. Carol Ann Cote, M.S., CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 104 Ironworks Rd, Clinton, CT 06413 Phone: 203-530-1233 Fax: 860-669-0536 |
News Archive
The New York Times reports that a "rogue cancer unit" at a veteran's hospital in Philadelphia "operated with virtually no outside scrutiny and botched 92 of 116 [prostate] cancer treatments over a span of more than six years - and then kept quiet about it, according to interviews with investigators, government officials and public records."
Axolotl Corp., the most experienced health information exchange (HIE) solutions and services company, today announced that it will be demonstrating its standards-based service-oriented architecture (SOA) platform — Elysium Open Access, with live third party applications – in operation today. Elysium Open Access is a core part of Axolotl's Elysium® Exchange HIE suite.
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).
A landmark research portal that includes health and biological data from 300,000 Canadians — nearly one in every 50 individuals between the ages of 35 and 69 – is being launched today by the Canadian Partnership Against Cancer (the Partnership).
AMAG Pharmaceuticals, Inc. today announced that the company has reached agreement with the U.S. Food and Drug Administration (FDA) regarding an update to the product label for Feraheme (ferumoxytol) Injection for intravenous (IV) use.
› Verified 1 days ago